Patent row between pharma companies referred to European court

It began when MSD sued Clonmel claiming the defendant was breaching its 2005 supplementary protection certificate , and extended patent protection, governing MSD’s authorisation for its drug “Inegy”.

MSD disputed Clonmel’s claims. It said once the combination has been the subject of a specific claim in patent, this was a complete answer to Clonmel’s case. However, the High Court rejected a third claim by Clonmel that the SPC was invalid because the marketing authorisation for the combination was not the first marketing authorisation for such combination and the SPC was granted contrary to the provisions of Article 3 of the regulation.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Conor Murray and Rory McIlroy help Whoop get on track for Irish marketing campaign | Business PostConor Murray and Rory McIlroy help Whoop get on track for Irish marketing campaign – emmetjryan reports. emmetjryan They'd want to get the orders right. Waiting 8 weeks for a band and no idea of when I will receive it
출처: businessposthq - 🏆 8. / 71 더 많은 것을 읽으십시오 »